


**Amendments to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:





**Listing of Claims:**


1-22. (canceled)

23. (Currently amended): A process for producing a antibiotic AA-896 compound of the formula



wherein:






or pharmaceutically acceptable salts thereof

said process comprising:




cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

24-30. (canceled)

31. (Currently amended): A process for producing a antibiotic AA-896 compound of the formula



wherein:




or pharmaceutically acceptable salts thereof

said process comprising:






cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

32. (Canceled)

33. (Currently amended): A process for producing a antibiotic AA-896 compound of the formula



wherein:




or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or an antibiotic AA-896 producing mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

34-39. (Canceled)

40. (Currently amended) A process for producing a antibiotic AA-896 compound of the formula




or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of *Streptomyces* spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

41. (Currently amended) A process for producing a antibiotic AA-896 compound of the formula



or pharmaceutically acceptable salts thereof

said process comprising:

cultivating a producing strain of *Streptomyces* spp. selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

42-86. (canceled)

87. (Currently amended): ~~A cultivated~~ An isolated microorganism *Streptomyces* spp. LL-AA896, strain LL4774 or an AA-896 antibiotic producing mutant thereof.

88. (Currently amended): The isolated microorganism of claim 87 wherein the AA-896 antibiotic producing mutant is strain LL4794, prepared by mutagenesis of strain LL4774.

89. (Currently amended): The isolated microorganism of claim 87 wherein the AA-896 antibiotic producing mutant is strain LL4802, prepared by mutagenesis of strain LL4774.

90. (Currently amended): The isolated microorganism of claim 87 wherein the AA-896 antibiotic producing mutant is strain LL4808, prepared by mutagenesis of strain LL4774.


91. (Currently amended): The isolated microorganism of claim 87 wherein the AA-896 antibiotic producing mutant is strain LL4879, prepared by mutagenesis of strain LL4774.

92. (Currently amended): The isolated microorganism of claim 87 wherein the AA-896 antibiotic producing mutant is strain LL4889, prepared by mutagenesis of strain LL4774.

93. (Currently amended): The isolated microorganism of claim 87 wherein the AA-896 antibiotic producing mutant is strain LL4892, prepared by mutagenesis of strain LL4774.


94-98. (Canceled):





99. (Currently amended): A process for producing a antibiotic AA-896 compound of the formula



or pharmaceutically acceptable salts thereof

wherein:






said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889 and LL4892 or an antibiotic AA-896 producing mutant thereof under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

100-103. (Canceled)

104. (Currently amended): A process for producing a antibiotic AA-896 compound of the formula




wherein:

$R^1$  is H or  $R^4$ ;

$R^2$  is H, OH or  $OCH_3$ ;

$R^3$  is H or  $CH_3$ ;

$R^4$  is represented by the formula



$n$  is an integer from 4 to 12;

$R^5$  is straight and branched alkyl of 1 to 4 carbon atoms, carbamimidoylamino or carbamimidoylhydroxyamino;

or a pharmaceutically acceptable salt thereof

said process comprising:

cultivating a producing strain of *Streptomyces spp.* selected from the group LL4774, LL4794, LL4802, LL4808, LL4889, LL4879 and LL4892 or an antibiotic AA-896 producing mutant thereof, under aerobic conditions, in a suitable culture medium until a recoverable amount of said antibiotic AA-896 compound is formed in said medium and recovering said antibiotic AA-896 compound therefrom.

105. (Previously presented): The process according to claim 104 wherein the producing strain is selected from the group LL4774, LL4794, LL4802, LL4808, LL4889, and LL4892.

106. (Previously presented) The process according to claim 23 wherein the producing strain of *Streptomyces spp.* is selected from the group LL4774, LL4794, LL4802, LL4808 and LL4892.

107. (Previously presented) The process according to claim 31 wherein the producing strain of *Streptomyces spp.* is selected from the group LL4774, LL4794, LL4802, LL4808, LL4879 and LL4892.

108. (Previously presented) The process according to claim 33 wherein the producing strain of *Streptomyces spp.* is selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892.

109. (Previously presented) The process according to claim 40 wherein the producing strain of *Streptomyces spp.* is selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, and LL4892.

110. (Previously presented) The process according to claim 41 wherein the producing strain of *Streptomyces spp.* is selected from the group LL4774, LL4794, LL4802, LL4808, LL4879, LL4889 and LL4892.

111. (Previously presented) The process according to claim 99 wherein the producing strain of *Streptomyces spp.* is selected from the group LL4774, LL4794, LL4802, LL4808, LL4889 and LL4892.